Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05138757 · ClinicalTrials.gov registry record · Phase 1
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05138757 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 20 participants.
The verdict
NCT05138757, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research is to gather information on the safety and efficacy of using a prebiotic as an adjunctive therapy to peanut oral immunotherapy. The prebiotic is not an FDA approved drug or medication rather a fiber found at local grocery stores.
Interventions
- DRUG Placebo
- DRUG Prebiotic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2025-03-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05138757
The ClinicalTrials.gov registry entry for NCT05138757 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05138757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05138757 about?
NCT05138757 is a clinical study titled "Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy". The purpose of this research is to gather information on the safety and efficacy of using a prebiotic as an adjunctive therapy to peanut oral immunotherapy. The prebiotic is not an FDA approved drug or medication rather a fiber found at local grocery stores.
What is the current status of trial NCT05138757?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-11-30. Estimated completion is 2025-03-12.
What interventions are being tested in trial NCT05138757?
The interventions under investigation include: Placebo (DRUG), Prebiotic (DRUG).
Who is sponsoring clinical trial NCT05138757?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.